Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Stroke. 2012 May 8;43(7):1925–1930. doi: 10.1161/STROKEAHA.111.647982

Figure 2.

Figure 2

Bevacizumab treatment reduced vessel density in VEGF-induced angiogenic foci. (A) Representative images of vessels labeled with lectin (green). Scale bar: 100 μm. (B) Bar graphs show quantification of vessel density. Administration of 5, 10, and 15 mg/kg bevacizumab significantly reduced vessel density as compared to trastuzumab treated control (*p<0.05). (C) Dose-inhibitory curve. The projected IC50 for bevacizumab anti-angiogenic effect is 1.06 mg/kg.